David Nemazee

List of Publications by Citations

Source: https://exaly.com/author-pdf/4678982/david-nemazee-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125 papers	8,868 citations	45 h-index	93 g-index
139 ext. papers	10,855 ext. citations	16.6 avg, IF	6.22 L-index

#	Paper	IF	Citations
125	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science*, **2020**, 369, 956-963	33.3	906
124	Rational HIV immunogen design to target specific germline B cell receptors. *Science*, **2013**, 340, 711-6	33.3	519
123	Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. *Science*, **2006**, 314, 1936-8	33.3	483
122	Broad neutralization of SARS-related viruses by human monoclonal antibodies. *Science*, **2020**, 369, 731-736	33.3	376
121	Peripheral deletion of self-reactive B cells. *Nature*, **1991**, 354, 308-11	50.4	318
120	HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. *Science*, **2015**, 349, 156-61	33.3	264
119	Receptor editing in lymphocyte development and central tolerance. *Nature Reviews Immunology*, **2006**, 6, 728-40	36.5	255
118	Contribution of receptor editing to the antibody repertoire. *Science*, **2001**, 291, 1541-4	33.3	252
117	Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. *Immunity*, **1997**, 7, 765-75	32.3	246
116	Revising B cell receptors. *Journal of Experimental Medicine*, **2000**, 191, 1813-7	16.6	223
115	V(D)J recombination in mature B cells: a mechanism for altering antibody responses. *Science*, **1997**, 278, 298-301	33.3	222
114	Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection. *Cell*, **1998**, 92, 173-82	56.2	204
113	Mechanisms of central tolerance for B cells. *Nature Reviews Immunology*, **2017**, 17, 281-294	36.5	183
112	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. *Cell*, **2016**, 166, 1459-1470.e11	56.2	178
111	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. *Immunity*, **2018**, 48, 133-146.e6	32.3	173
110	Receptor selection in B and T lymphocytes. *Annual Review of Immunology*, **2000**, 18, 19-51	34.7	170
109	Receptor editing occurs frequently during normal B cell development. *Journal of Experimental Medicine*, **1998**, 188, 1231-8	16.6	168

108	Polyspecificity of T cell and B cell receptor recognition. *Seminars in Immunology*, **2007**, 19, 216-24	10.7	159
107	BCR ligation induces receptor editing in IgM+IgD- bone marrow B cells in vitro. *Immunity*, **1997**, 6, 429-36	32.3	158
106	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. *Science*, **2021**, 371, 823-829	33.3	157
105	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. *Science*, **2020**, 370, 1089-1094	33.3	153
104	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. *Science*, **2021**, 373, 818-823	33.3	148
103	Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. *Journal of Experimental Medicine*, **2010**, 207, 173-87	16.6	120
102	Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells. *Journal of Experimental Medicine*, **1997**, 186, 1513-22	16.6	118
101	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *Nature Communications*, **2021**, 12, 2938	17.4	110
100	V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling. *Nature*, **1998**, 394, 292-5	50.4	105
99	Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. *Nature Communications*, **2016**, 7, 12041	17.4	101
98	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. *Journal of Experimental Medicine*, **2017**, 214, 2573-2590	16.6	100
97	High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. *Cell Reports*, **2016**, 15, 1986-99	10.6	89
96	The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. *Nature Immunology*, **2016**, 17, 433-40	19.1	88
95	Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. *Journal of Immunology*, **2013**, 191, 3186-3191	5.3	81
94	Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection. *Journal of Immunology*, **2007**, 178, 6332-41	5.3	81
93	Regulation of the B cell receptor repertoire and self-reactivity by BAFF. *Journal of Immunology*, **2010**, 185, 4128-36	5.3	74
92	The P4-type ATPase ATP11C is essential for B lymphopoiesis in adult bone marrow. *Nature Immunology*, **2011**, 12, 434-40	19.1	73
91	Antigen receptor Scapacity and the sensitivity of self-tolerance. *Trends in Immunology*, **1996**, 17, 25-9		69

90	A role for nuclear factor kappa B/rel transcription factors in the regulation of the recombinase activator genes. *Immunity*, **2005**, 22, 519-31	32.3	68
89	A VH11V kappa 9 B cell antigen receptor drives generation of CD5+ B cells both in vivo and in vitro. *Journal of Immunology*, **2000**, 164, 4586-93	5.3	68
88	Antigen receptor selection by editing or downregulation of V(D)J recombination. *Current Opinion in Immunology*, **2003**, 15, 182-9	7.8	65
87	Distinct roles for E12 and E47 in B cell specification and the sequential rearrangement of immunoglobulin light chain loci. *Journal of Experimental Medicine*, **2009**, 206, 2271-84	16.6	64
86	PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing. *Nature Immunology*, **2018**, 19, 942-953	19.1	56
85	T cell-independent rescue of B lymphocytes from peripheral immune tolerance. *Science*, **2000**, 287, 2501-3	33.3	55
84	An immunoglobulin C kappa-reactive single chain antibody fusion protein induces tolerance through receptor editing in a normal polyclonal immune system. *Journal of Experimental Medicine*, **2005**, 201, 817-28	16.6	52
83	Regulation of B-cell development and tolerance by different members of the miR-17~92 family microRNAs. *Nature Communications*, **2016**, 7, 12207	17.4	50
82	Anti-HIV B Cell lines as candidate vaccine biosensors. *Journal of Immunology*, **2012**, 189, 4816-24	5.3	48
81	Receptor editing and commitment in B lymphocytes. *Current Opinion in Immunology*, **1998**, 10, 208-13	7.8	47
80	Skewed primary Igrepertoire and V-J joining in C57BL/6 mice: implications for recombination accessibility and receptor editing. *Journal of Immunology*, **2012**, 188, 2305-15	5.3	44
79	Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes. *Journal of Experimental Medicine*, **1998**, 188, 909-17	16.6	44
78	HIV-1 vaccine design through minimizing envelope metastability. *Science Advances*, **2018**, 4, eaau6769	14.3	43
77	Rearrangement of mouse immunoglobulin kappa deleting element recombining sequence promotes immune tolerance and lambda B cell production. *Immunity*, **2008**, 28, 161-70	32.3	40
76	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection **2020**,		40
75	FGD2, a CDC42-specific exchange factor expressed by antigen-presenting cells, localizes to early endosomes and active membrane ruffles. *Journal of Biological Chemistry*, **2008**, 283, 34002-12	5.4	39
74	The scope of receptor editing and its association with autoimmunity. *Current Opinion in Immunology* , **2004**, 16, 808-14	7.8	36
73	Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model **2020**,		35

72	Reduced receptor editing in lupus-prone MRL/lpr mice. *Journal of Experimental Medicine*, **2007**, 204, 2853-64	16.8	34
71	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. *PLoS Pathogens*, **2020**, 16, e1009089	7.6	33
70	Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2. *Clinical Chemistry*, **2021**, 67, 404-414	5.5	32
69	B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. *Journal of Immunology*, **2013**, 191, 3179-85	5.3	31
68	Role of receptor editing and revision in shaping the B and T lymphocyte repertoire. *Life Sciences*, **2001**, 69, 1105-13	6.8	31
67	Reprogramming the antigen specificity of B cells using genome-editing technologies. *ELife*, **2019**, 8,	8.9	30
66	Receptor editing and genetic variability in human autoreactive B cells. *Journal of Experimental Medicine*, **2016**, 213, 93-108	16.6	28
65	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. *Molecular Therapy*, **2019**, 27, 2080-2090	11.7	27
64	A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes **2021**,		26
63	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants **2021**,		26
62	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. *PLoS Pathogens*, **2020**, 16, e1008665	7.6	25
61	Paucity of V-D-D-J rearrangements and VH replacement events in lupus prone and nonautoimmune TdT-/- and TdT+/+ mice. *Journal of Immunology*, **2006**, 177, 1120-8	5.3	24
60	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. *Cell Host and Microbe*, **2021**, 29, 806-818.e6	23.4	24
59	Deletion of IgG-switched autoreactive B cells and defects in Fas(lpr) lupus mice. *Journal of Immunology*, **2010**, 185, 1015-27	5.3	22
58	B cell clonal elimination induced by membrane-bound self-antigen may require repeated antigen encounter or cell competition. *European Journal of Immunology*, **2000**, 30, 689-96	6.1	22
57	Negative selection by IgM superantigen defines a B cell central tolerance compartment and reveals mutations allowing escape. *Journal of Immunology*, **2011**, 187, 5596-605	5.3	21
56	A mutation of Ikbkg causes immune deficiency without impairing degradation of IkappaB alpha. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 3046-51	11.5	20
55	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 22920-22931	11.5	20

54	2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies. *Journal of Virology*, **2013**, 87, 2234-41	6.6	18
53	Tolerance-induced receptor selection: scope, sensitivity, locus specificity, and relationship to lymphocyte-positive selection. *Immunological Reviews*, **2004**, 197, 219-30	11.3	18
52	Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein **2020**,		18
51	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. *Science Translational Medicine*, **2021**, 13, eabj5413	17.5	18
50	Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. *Nature Communications*, **2020**, 11, 5850	17.4	17
49	Peripheral B cell tolerance and function in transgenic mice expressing an IgD superantigen. *Journal of Immunology*, **2010**, 184, 4143-58	5.3	16
48	Liver-expressed Igkappa superantigen induces tolerance of polyclonal B cells by clonal deletion not kappa to lambda receptor editing. *Journal of Experimental Medicine*, **2011**, 208, 617-29	16.6	16
47	Suppression of IgE B cells and IgE binding to Fc(epsilon)RI by gene therapy with single-chain anti-IgE. *Journal of Immunology*, **2009**, 182, 8110-7	5.3	15
46	Effect of cell:cell competition and BAFF expression on peripheral B cell tolerance and B-1 cell survival in transgenic mice expressing a low level of Igkappa-reactive macroself antigen. *European Journal of Immunology*, **2006**, 36, 985-96	6.1	15
45	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.. *Science Translational Medicine*, **2022**, 14, eabi9215	17.5	15
44	The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8 Thymocyte Selection. *Journal of Immunology*, **2017**, 198, 2649-2660	5.3	14
43	Generation of T follicular helper cells in vitro: requirement for B-cell receptor cross-linking and cognate B- and T-cell interaction. *Immunology*, **2018**, 153, 214-224	7.8	14
42	Split tolerance in peripheral B cell subsets in mice expressing a low level of Igkappa-reactive ligand. *Journal of Immunology*, **2006**, 176, 939-48	5.3	14
41	MicroRNA control of B cell tolerance, autoimmunity and cancer. *Seminars in Cancer Biology*, **2020**, 64, 102-107	12.7	12
40	An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 **2020**,		11
39	Anti-laminin reactivity and glomerular immune deposition by in vitro recombinant antibodies. *Autoimmunity*, **1997**, 26, 231-43	3	10
38	Role of B cell antigen receptor in regulation of V(D)J recombination and cell survival. *Immunologic Research*, **2000**, 21, 259-63	4.3	10
37	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. *journal of applied laboratory medicine, The*, **2021**, 6, 1109-1122	2	10

36	Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. *Journal of Experimental Medicine*, **2019**, 216, 2331-2347	16.6	9
35	Can receptor editing play an important role in normal B-cell development?. *Journal of Autoimmunity* , **1996**, 9, 259-61	15.5	9
34	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate **2020**,		8
33	Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2		7
32	PLD3 and spinocerebellar ataxia. *Brain*, **2018**, 141, e78	11.2	7
31	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. *Blood*, **2019**, 134, 776-781	2.2	6
30	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants **2021**,		6
29	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens		4
28	Natural history of MZ B cells. *Journal of Experimental Medicine*, **2021**, 218,	16.6	4
27	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques		4
26	Do B cells take advantage of Smissing selfSrecognition?. *Current Directions in Autoimmunity*, **2003**, 6, 245-64		3
25	Haplotype exclusion and receptor editing: irreconcilable differences?. *Seminars in Immunology*, **2002**, 14, 191-8; discussion 222-4	10.7	3
24	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies.. *Nature Communications*, **2022**, 13, 462	17.4	3
23	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses **2021**,		3
22	Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution		3
21	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection **2021**,		3
20	Broadly neutralizing antibodies target the coronavirus fusion peptide. **2022**,		3
19	Receptor editing: genetic reprogramming of autoreactive lymphocytes. *Cell Biochemistry and Biophysics*, **1999**, 31, 81-8	3.2	2

18	Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors. *Nature Communications*, **2021**, 12, 5874	17.4	2
17	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody **2020**,		2
16	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. **2022**,		2
15	A broad and potent neutralization epitope in SARS-related coronaviruses. **2022**,		2
14	Peripheral B lymphocyte tolerance. *Keio Journal of Medicine*, **2004**, 53, 151-8	1.6	1
13	Vaccine Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells		1
12	B cells expressing authentic naive human VRC01-class BCRs can be primed and recruited to germinal centers in multiple independent mouse models		1
11	Reprogramming the antigen specificity of B cells using genomeediting technologies		1
10	In vivo engineered B cells retain memory and secrete high titers of anti-HIV antibodies in mice		1
9	Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin. *Frontiers in Immunology*, **2020**, 11, 431	8.4	1
8	Role of RS/kappaDE in B cell receptor editing. *Advances in Experimental Medicine and Biology*, **2007**, 596, 169-72	3.6	1
7	Prediabetes Induced by a Single Autoimmune B Cell Clone. *Frontiers in Immunology*, **2020**, 11, 1073	8.4	0
6	B Cells Carrying Antigen Receptors Against Microbes as Tools for Vaccine Discovery and Design. *Current Topics in Microbiology and Immunology*, **2020**, 428, 165-180	3.3	
5	Central B Cell Tolerance **2016**, 78-82		
4	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
3	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
2	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
1	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		